More than 700,000 people already die every year from drug-resistant bacterial infections. Unless action is taken, this number will reach 10 million people a year worldwide by 2050 (more than currently die from cancer). Pharmaceutical companies, together with governments and other stakeholders, have a crucial role in preventing this scenario.
The first-ever Antimicrobial Resistance Benchmark will map the actions of 30 pharmaceutical companies across three research areas: Research & Development, Manufacturing and Production, Access & Stewardship. The Benchmark will show where the pharmaceutical industry is taking action, which companies are leading, and where faster progress is needed.
http://www.weforum.org/
The first-ever Antimicrobial Resistance Benchmark will map the actions of 30 pharmaceutical companies across three research areas: Research & Development, Manufacturing and Production, Access & Stewardship. The Benchmark will show where the pharmaceutical industry is taking action, which companies are leading, and where faster progress is needed.
http://www.weforum.org/
- Category
- Success
Sign in or sign up to post comments.
Be the first to comment